ATE507293T1 - Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen - Google Patents

Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen

Info

Publication number
ATE507293T1
ATE507293T1 AT05854816T AT05854816T ATE507293T1 AT E507293 T1 ATE507293 T1 AT E507293T1 AT 05854816 T AT05854816 T AT 05854816T AT 05854816 T AT05854816 T AT 05854816T AT E507293 T1 ATE507293 T1 AT E507293T1
Authority
AT
Austria
Prior art keywords
gene silencing
sequences suitable
hcv sequences
hbv
conserved hbv
Prior art date
Application number
AT05854816T
Other languages
German (de)
English (en)
Inventor
Catherine Pachuk
Chandrasekhar Satishchandran
Vincent Zurawski
Liat Mintz
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE507293T1 publication Critical patent/ATE507293T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
AT05854816T 2004-12-22 2005-12-20 Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen ATE507293T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63829404P 2004-12-22 2004-12-22
PCT/US2005/046162 WO2006069064A2 (en) 2004-12-22 2005-12-20 Conserved hbv and hcv sequences useful for gene silencing

Publications (1)

Publication Number Publication Date
ATE507293T1 true ATE507293T1 (de) 2011-05-15

Family

ID=36602266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05854816T ATE507293T1 (de) 2004-12-22 2005-12-20 Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen

Country Status (7)

Country Link
EP (2) EP1833967B1 (enExample)
JP (3) JP2008525029A (enExample)
AT (1) ATE507293T1 (enExample)
AU (1) AU2005319306B9 (enExample)
CA (1) CA2592099A1 (enExample)
DE (1) DE602005027747D1 (enExample)
WO (1) WO2006069064A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575327B2 (en) * 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP2772541A3 (en) 2004-09-24 2014-09-24 Alnylam Pharmaceuticals Inc. Targeting opposite strand replication intermediates of hepatitis C virus by RNAi
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8642752B2 (en) 2011-04-21 2014-02-04 Isis Pharmaceuticals, Inc. Modulation of Hepatitis B virus (HBV) expression
WO2013119793A1 (en) * 2012-02-07 2013-08-15 University Of Kansas Chemiluminescent nanoparticles and uses thereof
WO2013159109A1 (en) * 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
EP3135765A1 (en) * 2012-12-06 2017-03-01 Sigma-Aldrich Co. LLC Crispr-based genome modification and regulation
MX377258B (es) * 2013-11-28 2025-03-07 Bavarian Nordic As Composiciones de vectores poxvirus y su uso para inducir una respuesta inmunitaria.
SG11201703638XA (en) 2014-11-10 2017-06-29 Alnylam Pharmaceuticals Inc Hepatitis b virus (hbv) irna compositions and methods of use thereof
CA2984512A1 (en) * 2015-05-06 2016-11-10 Benitec Biopharma Limited Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
AU2017260580B2 (en) 2016-05-05 2022-07-28 Benitec IP Holdings Inc. Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
CN110234763A (zh) * 2016-11-11 2019-09-13 詹森生物制药有限公司 针对hbv cccdna的寡核苷酸靶向策略
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
MA70658B1 (fr) 2018-08-13 2026-04-30 Alnylam Pharmaceuticals, Inc. Compositions d'agent d'arndb du virus de l'hépatite b (vhb) et leurs méthodes d'utilisation

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
EP0400047B1 (en) 1988-02-05 1997-04-23 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
WO1995027788A1 (en) * 1994-04-11 1995-10-19 Dainabot Co., Ltd. Polypeptide derived from variant hepatitis b virus, gene encoding the same, and related dna
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5874565A (en) 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5843770A (en) * 1996-03-11 1998-12-01 The Immune Response Corporation Antisense constructs directed against viral post-transcriptional regulatory sequences
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
AU745805B2 (en) 1997-10-28 2002-04-11 Wyeth Compositions and methods for delivery of genetic material
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
BR9908223A (pt) 1998-03-16 2000-10-24 Procter & Gamble Método para reduzir celulite na pele de mamìferos
CA2370628A1 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
EP1238061A2 (en) * 1999-11-24 2002-09-11 Pharmasset, Ltd. A new genotype of hepatitis b virus
JP2003515327A (ja) * 1999-12-03 2003-05-07 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｈｂｖ配列
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2002072763A2 (en) * 2001-03-09 2002-09-19 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
DE10163098B4 (de) * 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
CA2483609C (en) 2002-05-03 2012-09-18 Harman International Industries, Incorporated Sound detection and localization system
WO2004011624A2 (en) 2002-07-31 2004-02-05 Nucleonics, Inc. Double stranded rna structures and constructs, and methods for generating and using the same
US7303906B2 (en) 2002-09-06 2007-12-04 Wisconsin Alumni Research Foundation Competent bacteria
CA2502649A1 (en) 2002-10-18 2004-04-29 Nucleonics Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
CN101914532A (zh) * 2002-11-22 2010-12-15 生物智囊团株式会社 Rna干扰的目标碱基序列的搜索方法
US6673661B1 (en) 2002-12-20 2004-01-06 Taiwan Semiconductor Manufacturing Co., Ltd. Self-aligned method for forming dual gate thin film transistor (TFT) device
WO2004063375A1 (en) * 2003-01-15 2004-07-29 Hans Prydz OPTIMIZING siRNA BY RNAi ANTISENSE
WO2004078974A1 (ja) * 2003-01-24 2004-09-16 Tokyo Metropolitan Organization For Medical Research Ｃ型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸
EP1597351B1 (en) 2003-02-27 2012-04-18 Alnylam Pharmaceuticals Inc. METHODS AND CONSTRUCTS FOR EVALUATION OF RNAi TARGETS AND EFFECTOR MOLECULES
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
EP2284268A3 (en) * 2003-06-12 2012-05-30 Alnylam Pharmaceuticals Inc. Conserved HBV and HCV sequences useful for gene silencing
WO2005007875A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Enhanced promoters for synthesis of small hairpin rna
WO2005007877A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Regulatable promoters for synthesis of small hairpin rna
US7985581B2 (en) * 2004-08-23 2011-07-26 Alnylam Pharmaceuticals, Inc. Multiple RNA polymerase III promoter expression constructs
JP5671371B2 (ja) * 2011-03-01 2015-02-18 株式会社山本鉄工所 連続プレス装置
JP2015086965A (ja) 2013-10-31 2015-05-07 株式会社エクセディ フライホイール組立体

Also Published As

Publication number Publication date
EP1833967A2 (en) 2007-09-19
JP2008525029A (ja) 2008-07-17
EP1833967B1 (en) 2011-04-27
AU2005319306B2 (en) 2012-01-12
JP2015003913A (ja) 2015-01-08
EP2316942A1 (en) 2011-05-04
CA2592099A1 (en) 2006-06-29
WO2006069064A3 (en) 2007-10-25
JP5934310B2 (ja) 2016-06-15
EP2316942B1 (en) 2021-04-21
WO2006069064A2 (en) 2006-06-29
DE602005027747D1 (de) 2011-06-09
AU2005319306A1 (en) 2006-06-29
JP2012223202A (ja) 2012-11-15
AU2005319306B9 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
DE602005027747D1 (de) Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
WO2011123645A3 (en) Nucleoside phosphoramidates
MY176918A (en) N- [ (2 ' r) -2' -deoxy-2' -fluoro-2' -methyl-p-phenyl-5' -uridylyl] - l-alanine 1-methylethyl ester and process for its production
EP2609923A3 (en) Nucleoside Phosphoramidates
DK1747023T3 (da) Fremgangsmåder og sammensætninger til formindskelse af HCV-virusgenommængder i en målcelle
DK1554301T3 (da) Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
EA200700243A1 (ru) Способы лечения гепатита с
MX2011007693A (es) Metodos para amplificar acidos nucleicos del virus de hepatitis c.
WO2010047830A3 (en) Agents for hcv treatment
JP2012136542A5 (enExample)
TW200728317A (en) Macrocylic inhibitors of hepatitis C virus
WO2007127801A3 (en) Hepatitis c virus infection biomarkers
DE60319820D1 (de) Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
WO2009091388A3 (en) Triazines and related compounds having antiviral activity, compositions and methods thereof
MX2012008443A (es) Nucleosidos antiviricos.
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
WO2010055164A3 (en) Isoquinolone derivatives as inhibitors of plavivirus replication
MX2011008641A (es) Compuestos heterociclicos antivirales.
EA200401362A1 (ru) Антивирусная терапия, основанная на противодействии рнк
WO2006038129A3 (en) Hepatitis c virus replication system
PH12022553394A1 (en) Conjugate of double-stranded sirna analogue
EP4410970A3 (en) Efficient cell culture system for hepatitis c virus genotype 6a
EA200802101A1 (ru) Конструкции-"шпильки" р15 и применение
TW201129362A (en) Heterocyclic antiviral compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties